Lyon, France, September 3, 2013 - Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study.
http://www.biospace.com/news_story.aspx?StoryID=307416&full=1
http://www.biospace.com/news_story.aspx?StoryID=307416&full=1
No comments:
Post a Comment